Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Edison had failure after failure tooo. Was Edison a failure?
As of Jan23 there were 11 million users of Think or Swim. Since the PR was only posted there today, for those individuals, it is a new PR.
Smart enough to have my own architectural office for over 40 years, professor at the university that I graduated from, NCARB certification (professional registration reciprocity in all states) but grew up in a family where English was more of a second language. Never claimed to be an English major but love when someone points outs out my perceived shortcomings.
*****KBLB - FAILURE AFTER FAILURE*****
NEW: 2023: Air Force Contract is a Slam Dunk - FAILED
NEW: 2023: Kings / MtheMovement to Purchase Up To $12 Million in Spidersilk - FAILED
NEW: 2023: Commercial production - FAILED
2022: Commercial production - FAILED
2022: Kings / MtheMovement to Purchase Up To $5 Million in Spidersilk - FAILED
2022: Website & apparel launch - FAILED
2021: Kings / MtheMovement to Purchase Up To $3 Million in Spidersilk - FAILED
NEW: 2021: "The Company ... has now produced enough silk to create a number of different fabric blends." - FAILED
2021: "Spydasilk should hit the ground running" - FAILED
2021: $250K prepayment from Kings / MtheMovement- FAILED
2019-2020: Uplist to NASDAQ - FAILED
2019: Commercial production - FAILED
2019: Appoint Independent Board of Directors - FAILED
2019: Polartec MOU - FAILED
2018: "Our recombinant spider silk silkworm technology is a direct drop-in replacement for traditional silkworms and allows us to move quickly, with minimal investment, to bring new products to market" - FAILED
2018: ““We are busy preparing silkworm eggs for shipment and putting the team in place at Prodigy to hit the ground running.” - FAILED
2016-2018: Army Contract - FAILED
NEW: 2016: “the Company is on schedule to produce all of the recombinant spider silk necessary to fulfill its contract with the US Government on time” - FAILED
2017: Mulberry facility in Texas - FAILED
2014-2015: "R&D .... is no longer necessary" - FAILED
2014-2015: “Scale and sale” - FAILED
2013-2015: Commercialization of Big Red - FAILED
2013-2014: Warwick Mills Partnership - FAILED
2013: SSM Industries Partnership - FAILED
And those are just a few of the MANY, MANY FAILURES that KBLB has had over the years….
We have been told over and over again that the company PRs are the ONLY way to know the real "truth" about KBLB.
OK, well, let's take a look at that so-called "truth" from some of KBLB's PRs over the years:
- How about the PR that (falsely) stated that they were going to make their 1st delivery around Oct 16, 2022?
<< It was a new PR >>
WRONG AGAIN!
Please show us today's "new PR" on KBLB's website....
https://www.kraiglabs.com/news/
You can't, because there is no PR from today. The last PR was posted on Monday:
https://www.kraiglabs.com/kraig-biocraft-laboratories-spring-production-trials-exceed-expectations-for-the-production-of-the-companys-recombinant-spider-silk/
Trying to call today's PR a "new PR" is extremely disingenous (as are most of the posts from the rah rah pumpers).
<
You added one word that changed everything.
"BS"
BTW I wasn't wrong when I said you weren't right or wrong..... I was just giving you an easy out. You know " Happy Trails To You" I was simply giving you a pass, but you couldn't take it. As usual incomplete facts don't wash.
The two people were correct and you were wrong. It was a new PR to the outlets they just received.
So once again when you get right down to it you were wrong and half cocked again.
You could improve your image... try closing with this in the future.
YMIGH!!!! STAY TUNED!!!!
It's all GOOD!
<< doesn't make you right or wrong. >>
Of course I was correct (once again). You just hate to admit it. I have been correct for years upon years.
Two people on this board were claiming that it was a new PR:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174384405
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174385589
<< Today's post was the same as Monday's >>
Thanks for confirming exactly what I stated.
Web, I know you're upset after all these years your tenure is nearing an end.
If you must post something please include the facts.
There was a PR on Monday.
A great deal of usual go to outlets didn't get the PR.
Today it was posted on those outlets and hopefully to all outlets necessary. Today's post was the same as Monday's but for the outlets that didn't have it and it was dated today. Doesn't mean two PRs and doesn't make you right or wrong. Just misunderstood but you're used to that.
It’s not a new PR but is a continuation of the PR getting out to a broader audience. Action Monday was largely based on those that follow boards and/or receive emails. Yesterday the PR went out a little wider and market response was strong. Today it goes out to Schwab and Fidelity (possibly others?) and, again, some positive response.
Starting to wonder if this was an “accidental” formatting issue or planned rollout in phases, both to see reaction by audience and to keep the PR as a talker all week?
We are moving from development stage to producing. Trials have been completed. Production is beginning or has begun.
Entering a new era boys and girls. Buckle up.
W2R
Smart enough to know the difference between "then" and "than?"
I love how anyone who isn't in full agreement with a D is a "Trumpster."
<< This is NOT a reposting of the same BS that was posted Monday. >>
Yes, it is.
You people are so clueless. I feel sorry for all of you that actually believe all of this BS.
Here is the PR from Monday on KBLB's own website:
https://www.kraiglabs.com/kraig-biocraft-laboratories-spring-production-trials-exceed-expectations-for-the-production-of-the-companys-recombinant-spider-silk/
It is the exact same thing that is being reposted today on this board.
<
This is NOT a reposting of the same BS that was posted Monday. That's not even an opinion. That's an outright lie. It's called a PR. At what price will we never hear from you again???
I know you understand techniacls and i do not but do i spot a cup form?
Many thanks.
breaking 0.12 and imo 0.15 tomorow with expection for next week... IMO
Looks like a thin layer of resisitance imo....could be easy break upwards imo
<< New pr out. >>
That isn't a new PR. You are just reposting the same BS that came out on Monday (four days ago).
So does Schwab.
Fidelity has the news today.
If he is a Trumpster than he is smarter than I thought.
With the PR now being distributed to more outlets including Schwab I wouldn't be surprised to see an increase in volume and price. Let's see what happens today.
Kraig Biocraft Laboratories Spring Spider Silk Production Trials Exceed Expectations
GlobeNewswire
ANN ARBOR, Mich., May 09, 2024 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (KBLB.NaE) ("the Company" or "Kraig Labs"), announces today that the spring production trials of the Company's new BAM-1 hybrid parental strains have concluded, exceeding all expectations for scale, performance and robustness.
Kraig Labs reports that the spring production trials were an unabashed success. These trials proved that the Company's BAM-1 recombinant spider silk hybrids are ready for rapid production expansion. Simply stated, this has been the most fruitful and successful production cycle in the Company's history.
Renowned sericulture expert and Kraig Labs executive consultant, Dr. Nirmal Kumar, oversaw the production cycle from start to finish, including rearing and selective breeding. Careful and meticulous testing throughout the entire production trial demonstrated that the BAM-1 parental lines were the strongest and most resilient lines Kraig Labs has ever developed.
Observation and screening conducted throughout all phases of production exceeded all expectations for health and vigor within the colony. Not a single instance of disease or infection was detected at any point during the entire cycle. This result surprised local silkworm experts observing the trials. Working with mundane silkworms, they had never experienced an entire production cycle from egg to egg without any disease in a batch of thousands of silkworms.
Under the guidance of Dr. Nirmal Kumar and through a meticulous, statistically-based selective breeding protocol, the parental strains for the BAM-1 hybrid were further optimized during the production cycle. The enhancements to the parental lines from this careful breeding program were designed to deliver larger cocoons with improved reeling characteristics and higher yields.
"I am proud of the work accomplished and very impressed by the performance of the BAM-1 silkworm lines," Dr. Nirmal Kumar, stated. "The luster of the BAM-1 silk is very unique and desirable. When paired with its strength, we have created a silk that can't be matched. The results of these trials exceeded our expectations. We are now on a solid foundation to scale production of the BAM-1 hybrid to metric ton levels."
"The BAM-1 parental lines have proven to be the strongest and most resilient we have ever fielded," said Company founder and CEO, Kim Thompson. "This production run greatly exceeded our targets and has prepared us for the next phase of our business plan. With these production trials successfully concluded, we are now aggressively implementing the next phase of our business plan, which will expand our operations and target multiple production locations in multiple countries."
Thompson and Dr. Nirmal Kumar have spent the last two months directly overseeing these trials, selecting facilities for expansion, reviewing operational protocols, and meeting with officials and business leaders regarding the Company's immediate plans. Thompson is now returning to the U.S. to enact the next stages of its spider silk production expansion plan and complete the Company's transition from a technology developer to a large-scale spider silk manufacturer.
Thompson and Dr. Nirmal Kumar have spent the last two months directly overseeing these trials, selecting facilities for expansion, reviewing operational protocols, and meeting with officials and business leaders regarding the Company's immediate plans. Thompson is now returning to the U.S. to enact the next stages of its spider silk production expansion plan and complete the Company's transition from a technology developer to a large-scale spider silk manufacturer.
The BAM-1 parental lines have proven to be the strongest and most resilient we have ever fielded," said Company founder and CEO, Kim Thompson. "This production run greatly exceeded our targets and has prepared us for the next phase of our business plan. With these production trials successfully concluded, we are now aggressively implementing the next phase of our business plan, which will expand our operations and target multiple production locations in multiple countries."
"I am proud of the work accomplished and very impressed by the performance of the BAM-1 silkworm lines," Dr. Nirmal Kumar, stated. "The luster of the BAM-1 silk is very unique and desirable. When paired with its strength, we have created a silk that can't be matched. The results of these trials exceeded our expectations.
New pr out. The company just shifted a gear up.
You think Mojocash and igotthemojo are the same because the aliases were created two weeks apart. Thin ice. Very very thin. Even if they were the same individual, Mojocash has not posted on the KBLB board on IHub to my knowledge.
I believe they are two different people with similar names. Sorry.
I guess he didn’t Google that one. One of his many original thoughts….. LMAO
$$$KBLB$$$$
"MM = Market Makers"
Exactly, but don't confuse him .
The easiest way to resolve this is to click on the name of an individual and look at their history of posts. If you go back through Mojo’s posts, you will see that his current user name has posts that were skeptical (especially of Thompson) and are now more favorable.
IHub won’t allow two different users to have the same user name. It would be easy for someone to ‘fake’ an identity that way.
In short, whatever the data you have, I don’t believe that there are two posters with the same ‘Mojo’ IHub name.
Money managers have no interest in keeping the share price down. When the volume of shares traded is zero, they make no money at all. When the volume of shares is high, they can make their money.
The shifts in price are due to investors and traders who are trying to buy and sell shares in a stock. When someone offers a premium and their order is filled, the stock will jump down to the average level investors are willing to buy/sell shares.
If you want the share price to go up, buy a lot of shares at a high price. Might I suggest you put in an order to buy 10 million shares at a dollar a share? That will drive the share price up to a dollar/share … until your order is filled.
SMH
Hoping for two PR’s this week, fingers crossed, let’s go kb
You have 2 different identities, I’ve proven that. You’re a fake Mr mojo. I want nothing more than KBLB to succeed. You have been on both sides. At least I’ve proven you to be 2 different people.
Honestly, I’ve honestly thought of you as an idiot. I’ve just never said it out loud. But since you’ve praised it out loud, yes. Mojo is a fucken idiot. Congrats moron.
well, im still gonna be here, so you are going to look like an idiot...or more of an idiot...
would 3 weeks be even more or less funny?...
Hey, they’ll come up with the truth, if you disappear they’ll know ! I always thought you were a fraud ! I only want the best for this group !! Good bye mojo. Guys, beware. I’ve posted all I need.
Since 2006 , you’ve been separated by 3 weeks. One, you’ve paid the premium. The other you’ve paid nothing. 2 WEEKS difference in signing up ?!?! Seriously brother ?!?!
Well, we’ll see what they have to say Mr MOJO. 2 weeks apart is kind funny don’t you think ? You’ve been living 2 different lives brother.
Seriously !? Mojo out of the Austin power movies ? Are you freaking mad ? Ray, that is the lamest excuse I could think of mate ! Nice try, not gonna do it though mate.
The last of 3 Austin powers movies came out in 2002, from what I can see. Mojo was quite a popular catch word. You would expect to see it used in usernames by different people and in different ways.
I wouldn't judge arguments on whether or not someone has multiple user names. Fake arguments are webslingers MO. Pretty easy to poke holes in bad speculation and arguments. No need for the username police and conspiracies.
YOU ARE A FAKE MOJO ! I’VE PROOVED IT ASSHOLE !
2 weeks apart in 2006 ? Good bye. Think of a different name. Not close to thebeastmugabi. He was a much better fighter than you.
You are busted fool !!
" Administration is taking a look at it now. They’ll get it straightened out."
so if im still here in a few days, then that will mean you are full of shit...
sounds good to me...
I personally am getting a vibe that KBLBs share price will be in the dollar range very soon.. moving on to multiple dollars before we naturally uplist to the nasdaq. Is it really that hard to imagine that this company could soon be worth billions if not 10’s of billions of dollars within the next 12 months?
We have a unique, game changing product. Endless possible uses. Contracts, partnerships, royalties.
I cannot understand why some people stay on a stock board every single day just to bash it. If you are a paid basher, well then I guess it’s your job.
Me personally, I don’t read any stock boards that I’m not affiliated with never less post on these boards daily.
If you don't have the funds to buy shares and missed the boat, then I am truly sorry. But don’t hang around in envy of us long term shareholders. Life is too short. Go for a walk and get an ice cream.
But it’s a free world. Do what you like. Just don’t expect me to think you actually have a life.
Followers
|
642
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
281873
|
Created
|
05/04/08
|
Type
|
Free
|
Moderators MU_Redskin1 gimmegimmeminemine TRUISM WebSlinger |
Email: corporate@KraigLabs.com
KRAIG LABS WEBSITE FOR INVESTORS
Quarterly and Annual Reporting to the SEC is available on the Company's Website and EDGAR.
* Financial Statements * SEC Filings *
Outstanding Shares as of January 12, 2023
For issues or questions relating to share certificates or the transfer of securities please contact the company's transfer agent:
Olde Monmouth Stock Transfer Co., Inc.
200 Memorial Pkwy.
Atlantic Highlands, New Jersey 07716
Phone: (732) 872-2727
(since August 14, 2013)
Kraig Biocraft Laboratories, Inc. (KBLB) is the first company with a commercially feasible spidersilk to be mass produced.
Kraig Labs is a biotechnology company focused on the development of commercially significant high performance polymers and technical fibers. Kraig Lab's focus has been on the production of a transgenic silkworm incorporating specific gene sequences from the golden orb weaving spider. These specific gene sequences inserted are to enable the silkworm to spin a new recombinant fiber which incorporates spider silk proteins. With the scientific breakthrough announced on September 29, 2010, Kraig Labs is now working to commercialize the transgenic silkworms to compete in the garment industry silk market. The value for the chinese raw silk market alone is 3-5 billion per annum. With the creation of 20 seperate transgenic silkworms, all with unique properties, Kraig Labs is now working at an accelerated pace to build upon their first generation transgenic organisms to develop their second generation of transgenic silkworm incorporating spider silk proteins. The scientists nearly doubled the strength of the silkworm with these specific spider gene insertions. Their second generation of transgenics are expected to be complete in 2011. These second generation organisms are to be compared with the strength, flexibility and resiliency of the native spider in which the gene sequences are derived from. These fibers which will match the strength of spider silk are expected to compete in the technical textiles market valued in excess of 120 billion per annum. The 3rd generation organisms are currently in the planning phase. These organisms are expected to spin fibers exceeding the strength of native spiders and may incorporate gene sequences that release an antibiotic, or to help reduce scarring with use in bandages.
Kraig Biocraft Laboratories has a sponsored research and development program with the University of Notre Dame, and the University of Wyoming. The genetic work is occurring at the University of Notre Dame, headed by Dr Malcolm Fraser, Phd. The gene sequences are derived from Dr. Randy Lewis's(University of Wyoming) patented gene sequences of the golden orb weaving spider. Kraig labs is paying for all expenses incurred for this research and development program, and thus Kraig Labs has exclusive global commercialization rights with the technologies developed, including methods, organisms, and fibers produced.
MANAGEMENT
Kim Thompson, Founder and CEO
As the CEO of the company, Mr. Thompson is the only member of the scientific advisory board who is also
a part of the corporation's management. His formal education lies in the fields of economics and law.
He received his B.A. in Applied Economics from James Madison College at Michigan State University.
He received his Juris Doctorate from the University of Michigan Law School in 1994.
Mr. Thompson founded Kraig Biocraft Laboratories in his pursuit of the development of new biotechnologies
with industrial applications. As chairman of the scientific advisory board, he brings a unique perspective,and
acts as the primary liaison between the advisory board and the corporation.
Mr. Thompson brings a wealth of experience in business management and consultation to Kraig. Following
the completion of his undergraduate degree, Mr. Thompson joined California Craftsman, Inc. as a
Vice-President with primary responsibility for both marketing and human resources.
Kim Thompson was the director of business development at Franchise Venture Partners, LLC. He subsequently
joined the firm of Shearson, Lehman, Hutton where he specialized in equity trading and research of small cap
companies. Mr. Thompson received the highest series seven score for all Shearson brokers in his class nationwide.
His experience in those small cap equity markets has proven to be invaluable both in his legal and business successes.
Prior to becoming a public company CEO, Mr. Thompson was the founder and senior litigation partner in a California
commercial law firm where he worked as corporate and litigation counsel to privately held and public companies.
His many accomplishments in corporate law include winning and collecting in full what his firm believes to have been
the largest award of lost profits in a California commercial arbitration up to that time. An important part of his work was
winning victories on behalf of corporate clients in disputes over intellectual property and distribution rights. He has
represented business clients ranging from small start ups and micro caps to Fortune 100 companies.
With a background in business leadership and in advising public and private corporations, Kim Thompson continues
to bring a unique perspective to the successful management of business. His extensive business and legal background
enables him to create practical solutions to business problems and seize opportunities for growth.
Mr. Thompson is a member of the Triple Nine Society for persons with documented genius level IQs (having tested above
the 99.9th percentile). He is also active in the realm of science and invention where he has to his credit a number of
provisional patent applications including innovations in the areas of biotechnology, organic polymers, genetic engineering
and magnetic field manipulation, among others.
Mr. Rice has over 13 years’ experience growing development stage businesses with a focus on technology development, commercialization, and go to market strategies. Mr. Rice holds a B.S. in Chemical engineering from Michigan Technological University.
Prior to joining Kraig Biocraft Laboratories Mr. Rice was the Director of Advanced Technologies for Ultra Electronics, AMI. In this role, Mr. Rice was responsible for the identification, capture, and execution of new technology programs. During his tenure with AMI, Rice secured more than twenty five million dollars in funded development programs from the US Department of Defense which his team successfully leveraged into commercially viable spinoff products. Mr. Rice was also responsible for technical sales, marketing, and promotion of AMI’s products and capabilities. Rice joined AMI as the third full time employee and helped to lead the organization through its rapid growth and ultimate acquisition by Ultra Electronics in 2011.
Earlier in his career Mr. Rice developed unique advanced manufacturing techniques, established and trained a production staff, led engineering development, authored numerous technical papers, and is a recognized subject matter expert. Mr. Rice holds 5 issued patents and numerous provisional patents.
Mr. Rice brings a history of transforming revolutionary ideas into viable commercial products.
Mr. Rice is currently completing his Masters of Business Administration through the Executive Program at the Eli Broad College of Business: Michigan State University.
Despite the huge potential of genetically modified animals outside of laboratory research, commercialisation of these animals has been extremely limited. Numerous factors, including negative consumer perception, regulatory hurdles, and limitations inherent to classical GM technologies, have kept the majority of GM animal applications within the realm of academic research. However genome editing using zinc finger nucleases could help develop new markets for the future commercialisation of GM animals.
Genetic modification is commonplace throughout the life sciences sector, from fundamental research to pharmaceutical testing. GM cellular and animal models are valuable tools for the study of many chronic diseases, the testing of pharmaceutical compounds and the development of new therapeutic strategies. Genetic modification also offers great benefits in vaccine and biopharmaceutical manufacturing, which rely heavily on the use of GM organisms for biomolecule design and production. Modifying the genome of an organism or cell line allows the incorporation of target biomolecules in specific biological contexts, as well as the transfer of a gene product from a low-producing organism to one that can produce on a commercial scale. These applications have been widely accepted for many years, with countless GM organisms approved for medical manufacturing applications by drug regulators in all major countries. Despite this widespread success within the research and pharmaceutical sectors, the use of GM organisms outside of these markets has been limited.
Despite the lack of broad acceptance for most commercial applications of GM animal products, this technology has been able to gain traction in a few market sectors. The most obvious application has been the commercialisation of transgenic animals for the production of biomolecules for therapeutic use. Cattle, sheep and goats have been used for large-scale production of antibodies, steroids and hormones - most notably insulin - for many years. In 2009, GTC Biotherapeutics received US FDA approval for bioproduction of a recombinant human antithrombin. This product - ATryn - is extracted from the milk of transgenic goats, and is the first approved biopharmaceutical to be produced using genetically engineered animals. Although this is a significant breakthrough for the commercialisation of GM animals, it is still within the pharmaceutical industry, and is a natural progression of existing cell-based technologies. Of potentially greater commercial interest is the extension of genetic engineering outside of this sector, into areas such as food production, textiles and even companion animals.
GM crops have been available in many countries since the early 1990s, and numerous cash crops - including sugar beet, soybean, corn and tomatoes - have been modified to improve resistance to disease, increase the rate of growth or enhance nutritional value. However, cultivation of these transgenic crops is generally tightly regulated, particularly within the European Union, and this, together with negative public opinion, has limited the more widespread development of GM technologies.
Similar to GM crops, many of the animals currently under development are intended to confer disease resistance, an application particularly suited to the use of zinc finger nuclease (ZFN) technology. Many diseases can be treated by the targeted deletion or modification of a host gene. With ZFNs, these targets can be modified with no footprint of genetic engineering. Due to the high costs of raising livestock, another area of focus in developing commercial GM animals has been increasing the rate of growth or size of animals. Among the first GM animals likely to be launched is a fast growing salmon from AquaBounty. The AquAdvantage Salmon is designed to reach market size in half the time of a wild type salmon, reducing costs for fish farmers and limiting the environmental impact of salmon farming by avoiding the need for ocean pens.
Although genetic engineering of animals for food is primarily driven by economic pressures, GM technologies have also been used in the companion animals market. In this sector, genetic modification can be used for practical purposes - such as the creation of hypoallergenic animals or the correction of heritable congenital defects which have arisen though inbreeding - or for purely cosmetic purposes, such as GloFish. The first example of a GM pet, GloFish are fluorescent zebrafish (Danio rerio) that have had genes encoding naturally fluorescent proteins (GFP, YFP, RFP) inserted into their genome. Developed by a group at the National University of Singapore, GloFish were originally created to develop live detection systems for water pollution. They were introduced as pets in the United States in 2003 following over two years of extensive environmental research and consultation. In Europe however, the sale and possession of GloFish is prohibited by rigorous legislation concerning the use of GM technologies.
By allowing precisely targeted insertion of spider genes and concomitant removal of endogenous silkworm silk genes at the same locus, ZFN technology offers the potential for development of transgenic silkworms which will produce native spider silk at commercially viable levels
Perhaps even more interesting from a commercial perspective is the use of GM animals in the manufacture of textiles. Silkworms - actually the larval form of the silkmoth Bombyx mori - have been used for the production of silk for thousands of years, with natural silk still produced by the cultivation of silkworms today. Silkworm cocoons are unwound to create linear silk threads, then re-spun into textiles in much the same way as cotton. Although the applications of silkworm silk are numerous, due to their unique physical and chemical properties, there is also widespread interest in the silks of several other insects.
Spider silk, in particular, offers numerous possibilities within the technical textiles industry, due to its incredible tensile strength and elasticity; characteristics which have not yet been replicated in synthetic materials. Like all insect silks, spider silk fibres consist of repetitive units of protein crystals separated by less structured protein chains. The exact properties and composition of each spider silk vary with its intended function. Major Ampullate or dragline silk, for example, is relatively hydrophobic with very high tensile strength and toughness, as it is used to form the outer rim and spokes of a web. In contrast, hydrophilic capture spiral silks, which form the inner structures of the web, are sticky and highly elastic to effectively entrap prey. This high degree of variability offers enormous potential for the textiles industry, raising the possibility of tailoring the properties of silk to create advanced technical fabrics, for applications such as bulletproof vests, parachute canopies and automobile airbags; biomedical applications, including sutures and tendon and ligament repair; new fabrics, for sportswear and clothing; and even microelectronics.
Although the use of spider silks for microsutures has recently been reported, more widespread application of spider silk technologies is currently limited by the difficulty in producing silks on a commercially viable scale. This is due to the difficulties of rearing spiders in large numbers, due to their highly territorial and cannibalistic nature. As a result, the harvesting of spider silk fibres is extremely time consuming and labour intensive, with production of the only known spider silk garment - an 11 foot by 4 foot shawl made from golden orb spider silk - taking 150 people over five years to produce and costing in excess of £300,000!
.
To overcome these limitations, and allow future development of spider silk technologies, an alternative strategy for spider silk production is required. This makes spider silk production an obvious candidate for genetic modification, inserting spider silk genes into the genome
of other silk-making insects for bioproduction. For example, random insertion of orb spider silk genes into silkworms has allowed production of hybrid spider/silkworm silk using traditional silkworm farming strategies. The resulting hybrid silk contains approximately 10% spider silk
and has greater strength and durability than native silkworm silk, raising the possibility of using transgenic silkworms to produce pure spider silks.
Though straightforward in principle, the exchange of native silkworm genes for spider silk genes, alongside more widespread exploitation of genetic engineering, has been limited by the inherent restrictions of conventional GM technologies.
The generalised process of modifying an organism requires several capabilities, including:
While many different techniques exist for accomplishing each of these steps, most GM technologies offer a compromise between the efficiency of the technique and the ability to accurately and precisely target the locus of interest. Viral genomic delivery technologies effectively deliver nucleic acids to cells and organisms, but fall short on ability to target specific regions of the genome, generally only allowing random insertion of genetic material. In comparison, transposase technologies allow a greater degree of targeting, but leave unwanted traces of exogenous DNA in their wake. Other methods involve the introduction of naked DNA into the cell, which results in insertion into the genome at very low frequencies, usually at random, limiting this approach to organisms that can be economically cultivated at high densities and screened in large numbers. Simply put, most techniques for genetic manipulation are random, inefficient and leave a 'footprint' of foreign DNA. While this is usually tolerated in basic research, it is not acceptable for most commercial applications, and has been a major hurdle for GM animal technologies to date.
The advent of zinc finger nuclease (ZFN) technology represents a significant breakthrough for commercialisation of GM animal products, offering precisely targeted, efficient genome editing for the first time. Commercially available through Sigma Life Science under the CompoZr brand, this technique can be used to create permanent and heritable changes to an organism of interest.
This high degree of variability offers enormous potential for the textiles industry, raising the possibility of tailoring the properties of silk to create advanced technical fabrics
ZFNs are a class of engineered DNA binding proteins that facilitate targeted editing of the genome by creating double-strand breaks at user-specified locations. These breaks stimulate the cell's natural DNA repair mechanisms - homologous recombination (HR) and non-homologous end joining (NHEJ) - which can be exploited to achieve rapid and permanent site-specific modification of the desired genes. While HR can be used to insert foreign DNA sequences, NHEJ allows the cell's natural processes to create precisely targeted mimics of natural mutations which leave no traces of foreign DNA. Unlike previous techniques, ZFNs offer excellent sequence specificity, binding 24 to 36 base pair target sequences to virtually eliminate off target effects, and are able to achieve modification rates exceeding 20 %, well above rates for most other technologies.
The technique is already being used to create transgenic silkworms for spider silk production. By allowing precisely targeted insertion of spider genes and concomitant removal of endogenous silkworm silk genes at the same locus, ZFN technology offers the potential for development of transgenic silkworms which will produce native spider silk at commercially viable levels.
GM technologies have revolutionised the research world and have great potential in a variety of commercial applications, but have been limited by the inherent restrictions associated with historical GM technologies. The main drawback of these technologies is their inability to accurately and efficiently target genes of interest, instead relying on random insertion of genetic material into host genomes. These limitations result in the need for extensive and costly screening to identify animals with correct transgene expression (without compromising the viability of the animal), and also result in the co-expression of both the transgene and native homologues already present.
The advent of ZFN technology signifies the beginning of an exciting new chapter in the world of genetic modification, allowing precise, targeted and efficient genome editing for the first time. Production of native spider silk using transgenic silkworms is just one example of the potential commercial applications of this innovative technology, taking us one step closer to the reality of industrial scale biomanufacturing and paving the way for an entirely new spectrum of environmentally friendly materials.
Authors:
Joseph Bedell and Brian Buntaine
Commercial Animal Technologies Group, Sigma Advanced Genetic Engineering (SAGE) Labs, Sigma Life Science
HEADLINES FOR KRAIG BIOCRAFT LABORATORIES / (KBLB):
PHOTOS FROM VIETNAM POSTED JULY 6, 2018
ANN ARBOR, Mich., – January 7, 2019 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers, announces today that it has successfully delivered the first two shipments of its highly specialized silkworms, which produce a silk with the physical characteristics of spider silk, to Vietnam.
Today’s announcement is the culmination of more than 5 years of work, and challenging negotiation, with the government of Vietnam. The silkworms from these first two shipments have already hatched and are now enjoying a fresh mulberry diet, so, for the first time in history, the global demand for spider silk materials has a viable, cost effective, and scalable solution.
“The dream of commercializing our powerful technology is now materializing. This marks a dramatic leap forward in Kraig Labs’ business plan for commercial production and mass marketing of cost effective recombinant spider silk, and becomes the foundation for an entirely new industry,” said, COO, Jon Rice. “To our long-term shareholders, who have taken this journey with us, as well as our team in the US and Vietnam, who have worked tirelessly to make this dream a reality, I cannot thank you enough. As we start the New Year, full of new opportunity, we truly have something incredible to celebrate.”
The Company has been working with leading sericulture experts, biotechnology institutions, and governmental agencies, in Vietnam, to further boost the silk industry with our revolutionary technology. Kraig Labs is currently finalizing renovation plans for a ~46,000 square foot production factory in Quang Nam Province, Vietnam.
“Our plan has always been to bring our technology to the silk producing regions of the world for rapid scale-up,” said, CEO and Founder, Kim Thompson. “Today we see the fruits of that effort. With its massive silk infrastructure and production capacity, Vietnam is an ideal location to launch our technology scale-up. Congratulations to our team and shareholders, as we prepare for the realization of large scale production.”
\
\
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |